pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 2·1 min read
save

Michel Detheux appointed CEO of Muna Therapeutics, GSK Alzheimer’s partner, as Genentech loses scientist Alex Hoffman

Jul 2, 2026·read at Endpoints ↗Neutral

Michel Detheux has taken over as chief executive of Danish neuro‑biotech Muna Therapeutics, succeeding Rita Balice‑Gordon in the role.

Muna Therapeutics continues its collaboration with GlaxoSmithKline, focusing on the development of treatments for Alzheimer’s disease under the new leadership.

In a separate move, Genentech announced the departure of a key scientist, Alex Hoffman, marking another loss for the company’s research team.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Ex-iTeos CEO starts fresh at GSK neuro partner; Genentech loses yet another key scientist”

read at Endpoints ↗
84 words · retrieved Jul 2
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
GENENTECH2GLAXOSMITHKLINE
topics
Neurology3HER22

related stories

  • May 8Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive
  • May 8Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive
  • May 8Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026onclive
  • May 6ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Goonclive
  • May 8Giants of Cancer Care Announces the 14th Annual Class of Inducteesonclive